<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 27 Mar 2025 16:14:25 +0000</lastbuilddate>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 26. doi: 10.1038/s41569-025-01149-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40140695</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01149-8>10.1038/s41569-025-01149-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40140695</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</dc:title>
<dc:identifier>pmid:40140695</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01149-8</dc:identifier>
</item>
<item>
<title>Aortic Valve Intervention for Asymptomatic Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136312/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136312/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40136312</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0483>10.1001/jamacardio.2025.0483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136312</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Rick A Nishimura</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Valve Intervention for Asymptomatic Aortic Stenosis</dc:title>
<dc:identifier>pmid:40136312</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0483</dc:identifier>
</item>
<item>
<title>Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the OCEANIC-AF randomized clinical trial, patients with AF who were OAC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding with asundexian compared with apixaban than patients who were OAC experienced. The mechanism of these findings is unknown and deserves further research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0277. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In patients with atrial fibrillation (AF), oral anticoagulants (OACs) reduce the risk of stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate if patients with less prior OAC exposure respond differently to a new OAC than patients with more OAC exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this prespecified exploratory subgroup analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic-Atrial Fibrillation (OCEANIC-AF) randomized clinical trial, patients enrolled in the OCEANIC-AF trial were categorized as OAC naive or OAC experienced based on whether they had 6 or fewer weeks or more than 6 weeks of prior OAC use. The effect of asundexian vs apixaban was then compared on outcomes among patients who were OAC naive and OAC experienced. The study setting included 1035 sites in 38 countries, and participants were those enrolled in the OCEANIC-AF trial. Data were analyzed from June to July 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Asundexian, a novel factor XIa inhibitor, was compared with apixaban in patients with AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was stroke or systemic embolism. The main safety outcome was major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of patients in the OCEANIC-AF trial, 2493 (17%) were OAC naive (mean [SD] age, 72.6 [8.6] years; 1464 male [59%]) and 12 317 (83%) were OAC experienced (mean [SD] age, 74.2 [7.5] years; 8132 male [66%]). In the asundexian arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.8% (10 of 1238) compared with 1.4% (88 of 6177) in those who were OAC experienced. In the apixaban arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.6% (7 of 1255) compared with 0.3% (19 of 6140) in those who were OAC experienced. Thus, patients who were OAC naive had a smaller increase in stroke or systemic embolism with asundexian compared with apixaban (hazard ratio [HR], 1.42; 95% CI, 0.54-3.73) than patients who were OAC experienced (HR, 4.66; 95% CI, 2.84-7.65; P for interaction =.03). Bleeding rates were lower among both OAC-naive patients (0.2% [2 of 1228]) and OAC-experienced patients (0.2% [15 of 6145]) assigned asundexian than among OAC-naive patients (1.0% [13 of 1249]) and OAC-experienced patients (0.7% [40 of 6115]) assigned apixaban.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the OCEANIC-AF randomized clinical trial, patients with AF who were OAC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding with asundexian compared with apixaban than patients who were OAC experienced. The mechanism of these findings is unknown and deserves further research.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05643573.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40136309</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0277>10.1001/jamacardio.2025.0277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136309</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Elizabeth J Lydon</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Thomas Viethen</dc:creator>
<dc:creator>Jonas Oldgren</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Jan Steffel</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Isabelle C van Gelder</dc:creator>
<dc:creator>Keith C Ferdinand</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Hardi Mundl</dc:creator>
<dc:creator>Bela Benczur</dc:creator>
<dc:creator>Juan José Gómez-Doblas</dc:creator>
<dc:creator>Michael Glikson</dc:creator>
<dc:creator>Assen Goudev</dc:creator>
<dc:creator>Erik L Grove</dc:creator>
<dc:creator>Sigrun Halvorsen</dc:creator>
<dc:creator>Tuomas Kiviniemi</dc:creator>
<dc:creator>Anne-Céline Martin</dc:creator>
<dc:creator>Roopinder K Sandhu</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Frank W Rockhold</dc:creator>
<dc:creator>Valeria Caso</dc:creator>
<dc:creator>Rosa Coppolecchia</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40136309</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0277</dc:identifier>
</item>
<item>
<title>Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In these 2 cluster randomized clinical trials, visit-based interruptive alerts were not associated with a significant increase in statin prescribing compared with usual care, whereas a strategy of asynchronous semiautomated referral for pharmacist comanagement was associated with a substantial increase. This strategy of asynchronous semiautomated referrals for pharmacist involvement in lipid management could be a scalable and effective approach to increasing statin...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0244. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Despite statins' benefit in preventing major adverse cardiovascular events, most patients with an indication for statin therapy are not appropriately treated. Clinicians' limited time and lack of systematic efforts to address preventive care likely contribute to gaps in statin prescribing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the effect on statin prescribing of 2 interventions to refer appropriate patients to a pharmacist for lipid management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: These 2 pragmatic cluster randomized clinical trials were conducted among 12 total primary care practices in a community health system. Trial 1 was a delayed-intervention design of a visit-based intervention with randomization at the clinician level in a single clinic, and trial 2 was a parallel-arm trial of an asynchronous intervention with randomization at the clinic level in 11 clinics. Patients who were assigned to a primary care clinician at a participating practice, had an indication for a high-intensity or moderate-intensity statin, and were either not prescribed a statin or prescribed an inappropriately low statin dose were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Trial 1 tested an interruptive electronic health record alert that appeared during eligible patients' visits and facilitated referral to a pharmacist, while trial 2 tested an order for pharmacist referral placed by the study team for cosignature by the primary care clinician without regard to the timing of a clinic visit.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: The primary outcome was the proportion of patients prescribed a statin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 1412 patients were enrolled in trial 1 and 1950 in trial 2. Across both trials, mean (SD) patient age was 65.6 (9.9) years, and 1485 patients (44.2%) were female. Mean (SD) baseline 10-year risk of major cardiovascular events was 17.9% (9.4). In trial 1, the interruptive alert was not associated with a significant increase in statin prescriptions compared with usual care (15.6% vs 11.6%; unadjusted absolute difference, 3.9 percentage points; 95% CI, -0.4 to 8.3). In trial 2, semiautomated pharmacist referrals were associated with an increase in statin prescriptions by 16 percentage points compared with usual care (31.6% vs 15.2%; unadjusted absolute difference, 16.4 percentage points; 95% CI, 12.7-20.1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In these 2 cluster randomized clinical trials, visit-based interruptive alerts were not associated with a significant increase in statin prescribing compared with usual care, whereas a strategy of asynchronous semiautomated referral for pharmacist comanagement was associated with a substantial increase. This strategy of asynchronous semiautomated referrals for pharmacist involvement in lipid management could be a scalable and effective approach to increasing statin prescribing for patients at high risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05537064.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40136263</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0244>10.1001/jamacardio.2025.0244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136263</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Qian Huang</dc:creator>
<dc:creator>Kayla Clark</dc:creator>
<dc:creator>Laurie A Norton</dc:creator>
<dc:creator>Wendell E Kellum</dc:creator>
<dc:creator>Dwight Eichelberger</dc:creator>
<dc:creator>John C Wood</dc:creator>
<dc:creator>Zachary Bricker</dc:creator>
<dc:creator>Andrea G Dooley Wood</dc:creator>
<dc:creator>Greta Kemmer</dc:creator>
<dc:creator>Jennifer I Smith</dc:creator>
<dc:creator>Srinath Adusumalli</dc:creator>
<dc:creator>Mary E Putt</dc:creator>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:40136263</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0244</dc:identifier>
</item>
<item>
<title>MAIT Cells Promote Cholesterol Excretion Pathways Mitigating Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40135347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings demonstrate a new mechanism for plasma VLDL-C clearance by MAIT cell-mediated cholesterol excretion. The results provide further evidence that immunity is involved in cholesterol homeostasis. Targeting intestinal immunity to regulate cholesterol homeostasis holds promise as a new cholesterol-lowering modality to prevent atherosclerotic cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 26. doi: 10.1161/CIRCRESAHA.124.325841. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Previous clinical studies have indicated reduced circulating mucosal-associated invariant T (MAIT) cells in individuals with coronary artery disease. However, the precise role and underlying mechanisms of MAIT cells in this context remain unclear. Immune homeostasis plays a pivotal role in the development of atherosclerosis. This study explores the impact of MAIT cells on atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Vα19<sup>+/-</sup> Ldlr<sup>-/-</sup> mice, characterized by a high MAIT cell frequency, and MAIT cell deficient MR1<sup>-/-</sup> (major histocompatibility complex-related molecule 1) Ldlr<sup>-/-</sup> mice and their respective controls were used. Starting at 6 weeks of age, mice were subjected to a 1% cholesterol diet for 16 weeks. Additionally, the study analyzed circulating MAIT cell frequency and cholesterol levels in 68 patients with hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In Vα19<sup>+/-</sup> Ldlr<sup>-/-</sup> mice, increased MAIT cells demonstrated a protective effect against atherosclerosis by reducing VLDL-C (very-low-density lipoprotein cholesterol) levels through heightened cholesterol excretion. This effect was accompanied by elevated jejunal ABCB1a, ABCG5, and ABCG8 expression, mediated by augmented levels of LXR transcription and activation, likely through intestinal IL-22 (interleukin-22) signaling. Conversely, cholesterol reduction mediated by intestinal cholesterol excretion was blocked by inhibition of MAIT cells. Moreover, MAIT cell-deficient MR1<sup>-/-</sup> Ldlr<sup>-/-</sup> mice exhibited elevated total cholesterol levels and increased atherosclerotic lesions. In patients with hypercholesterolemia, circulating MAIT cell frequency displayed negative correlations with VLDL-C levels and positive correlations with HDL-C (high-density lipoprotein cholesterol) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings demonstrate a new mechanism for plasma VLDL-C clearance by MAIT cell-mediated cholesterol excretion. The results provide further evidence that immunity is involved in cholesterol homeostasis. Targeting intestinal immunity to regulate cholesterol homeostasis holds promise as a new cholesterol-lowering modality to prevent atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40135347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40135347</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325841>10.1161/CIRCRESAHA.124.325841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40135347</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Hua Wang</dc:creator>
<dc:creator>Pukar K C</dc:creator>
<dc:creator>Kaidi Zhang</dc:creator>
<dc:creator>Clément Materne</dc:creator>
<dc:creator>Marie Lhomme</dc:creator>
<dc:creator>Sophie Galier</dc:creator>
<dc:creator>Farid Ichou</dc:creator>
<dc:creator>Carolina Neves</dc:creator>
<dc:creator>Agnes Lehuen</dc:creator>
<dc:creator>Joel T Haas</dc:creator>
<dc:creator>Joe-Elie Salem</dc:creator>
<dc:creator>Maryse Guerin</dc:creator>
<dc:creator>Philippe Lesnik</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>MAIT Cells Promote Cholesterol Excretion Pathways Mitigating Atherosclerosis</dc:title>
<dc:identifier>pmid:40135347</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325841</dc:identifier>
</item>
<item>
<title>Functional and antigenic landscape of the Nipah virus receptor-binding protein</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40132580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>Nipah virus recurrently spills over to humans, causing fatal infections. The viral receptor-binding protein (RBP or G) attaches to host receptors and is a major target of neutralizing antibodies. Here, we use deep mutational scanning to measure how all amino-acid mutations to the RBP affect cell entry, receptor binding, and escape from neutralizing antibodies. We identify functionally constrained regions of the RBP, including sites involved in oligomerization, along with mutations that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20:S0092-8674(25)00257-0. doi: 10.1016/j.cell.2025.02.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nipah virus recurrently spills over to humans, causing fatal infections. The viral receptor-binding protein (RBP or G) attaches to host receptors and is a major target of neutralizing antibodies. Here, we use deep mutational scanning to measure how all amino-acid mutations to the RBP affect cell entry, receptor binding, and escape from neutralizing antibodies. We identify functionally constrained regions of the RBP, including sites involved in oligomerization, along with mutations that differentially modulate RBP binding to its two ephrin receptors. We map escape mutations for six anti-RBP antibodies and find that few antigenic mutations are present in natural Nipah strains. Our findings offer insights into the potential for functional and antigenic evolution of the RBP that can inform the development of antibody therapies and vaccines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40132580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40132580</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.030>10.1016/j.cell.2025.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40132580</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Brendan B Larsen</dc:creator>
<dc:creator>Teagan McMahon</dc:creator>
<dc:creator>Jack T Brown</dc:creator>
<dc:creator>Zhaoqian Wang</dc:creator>
<dc:creator>Caelan E Radford</dc:creator>
<dc:creator>James E Crowe</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:creator>Jesse D Bloom</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Functional and antigenic landscape of the Nipah virus receptor-binding protein</dc:title>
<dc:identifier>pmid:40132580</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.030</dc:identifier>
</item>
<item>
<title>Enteric neuronal Piezo1 maintains mechanical and immunological homeostasis by sensing force</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40132579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>The gastrointestinal (GI) tract experiences a myriad of mechanical forces while orchestrating digestion and barrier immunity. A central conductor of these processes, the enteric nervous system (ENS), detects luminal pressure to regulate peristalsis independently of extrinsic input from the central and peripheral nervous systems. However, how the ∼500 million enteric neurons that reside in the GI tract sense and respond to force remains unknown. Herein, we establish that the mechanosensor Piezo1...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20:S0092-8674(25)00258-2. doi: 10.1016/j.cell.2025.02.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The gastrointestinal (GI) tract experiences a myriad of mechanical forces while orchestrating digestion and barrier immunity. A central conductor of these processes, the enteric nervous system (ENS), detects luminal pressure to regulate peristalsis independently of extrinsic input from the central and peripheral nervous systems. However, how the ∼500 million enteric neurons that reside in the GI tract sense and respond to force remains unknown. Herein, we establish that the mechanosensor Piezo1 is functionally expressed in cholinergic enteric neurons. Optogenetic stimulation of Piezo1<sup>+</sup> cholinergic enteric neurons drives colonic motility, while Piezo1 deficiency reduces cholinergic neuronal activity and slows peristalsis. Additionally, Piezo1 deficiency in cholinergic enteric neurons abolishes exercise-induced acceleration of GI motility. Finally, we uncover that enteric neuronal Piezo1 function is required for motility alterations in colitis and acts to prevent aberrant inflammation and tissue damage. This work uncovers how the ENS senses and responds to mechanical force.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40132579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40132579</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.031>10.1016/j.cell.2025.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40132579</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zili Xie</dc:creator>
<dc:creator>Lillian Rose</dc:creator>
<dc:creator>Jing Feng</dc:creator>
<dc:creator>Yonghui Zhao</dc:creator>
<dc:creator>Yisi Lu</dc:creator>
<dc:creator>Harry Kane</dc:creator>
<dc:creator>Timothy J Hibberd</dc:creator>
<dc:creator>Xueming Hu</dc:creator>
<dc:creator>Zhen Wang</dc:creator>
<dc:creator>Kaikai Zang</dc:creator>
<dc:creator>Xingliang Yang</dc:creator>
<dc:creator>Quentin Richardson</dc:creator>
<dc:creator>Rahmeh Othman</dc:creator>
<dc:creator>Olivia Venezia</dc:creator>
<dc:creator>Ademi Zhakyp</dc:creator>
<dc:creator>Fang Gao</dc:creator>
<dc:creator>Nobuya Abe</dc:creator>
<dc:creator>Keren Vigeland</dc:creator>
<dc:creator>Hongshen Wang</dc:creator>
<dc:creator>Camren Branch</dc:creator>
<dc:creator>Coco Duizer</dc:creator>
<dc:creator>Liwen Deng</dc:creator>
<dc:creator>Xia Meng</dc:creator>
<dc:creator>Lydia Zamidar</dc:creator>
<dc:creator>Max Hauptschein</dc:creator>
<dc:creator>Ronan Bergin</dc:creator>
<dc:creator>Xinzhong Dong</dc:creator>
<dc:creator>Issac M Chiu</dc:creator>
<dc:creator>Brian S Kim</dc:creator>
<dc:creator>Nick J Spencer</dc:creator>
<dc:creator>Hongzhen Hu</dc:creator>
<dc:creator>Ruaidhrí Jackson</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Enteric neuronal Piezo1 maintains mechanical and immunological homeostasis by sensing force</dc:title>
<dc:identifier>pmid:40132579</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.031</dc:identifier>
</item>
<item>
<title>Nanoscale DNA tracing reveals the self-organization mechanism of mitotic chromosomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40132578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>How genomic DNA is folded during cell division to form the characteristic rod-shaped mitotic chromosomes essential for faithful genome inheritance is a long-standing open question in biology. Here, we use nanoscale DNA tracing in single dividing cells to directly visualize how the 3D fold of genomic DNA changes during mitosis at scales from single loops to entire chromosomes. Our structural analysis reveals a characteristic genome scaling minimum of 6-8 megabases in mitosis. Combined with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 19:S0092-8674(25)00255-7. doi: 10.1016/j.cell.2025.02.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">How genomic DNA is folded during cell division to form the characteristic rod-shaped mitotic chromosomes essential for faithful genome inheritance is a long-standing open question in biology. Here, we use nanoscale DNA tracing in single dividing cells to directly visualize how the 3D fold of genomic DNA changes during mitosis at scales from single loops to entire chromosomes. Our structural analysis reveals a characteristic genome scaling minimum of 6-8 megabases in mitosis. Combined with data-driven modeling and molecular perturbations, we can show that very large and strongly overlapping loops formed by condensins are the fundamental structuring principle of mitotic chromosomes. These loops compact chromosomes locally and globally to the limit set by chromatin self-repulsion. The characteristic length, density, and increasingly overlapping structure of mitotic loops we observe in 3D fully explain how the rod-shaped mitotic chromosome structure emerges by self-organization during cell division.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40132578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40132578</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.028>10.1016/j.cell.2025.02.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40132578</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kai Sandvold Beckwith</dc:creator>
<dc:creator>Andreas Brunner</dc:creator>
<dc:creator>Natalia Rosalia Morero</dc:creator>
<dc:creator>Ralf Jungmann</dc:creator>
<dc:creator>Jan Ellenberg</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Nanoscale DNA tracing reveals the self-organization mechanism of mitotic chromosomes</dc:title>
<dc:identifier>pmid:40132578</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.028</dc:identifier>
</item>
<item>
<title>The Australian-New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40132048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf127. doi: 10.1093/eurheartj/ehaf127. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40132048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40132048</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf127>10.1093/eurheartj/ehaf127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40132048</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marysia S Tweet</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Australian-New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke</dc:title>
<dc:identifier>pmid:40132048</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf127</dc:identifier>
</item>
<item>
<title>Restrictive cardiomyopathy with unique fibrosis pattern and familial atrial arrythmia associated with DES mutation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131846/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf148. doi: 10.1093/eurheartj/ehaf148. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131846/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131846</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf148>10.1093/eurheartj/ehaf148</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131846</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Suolunge Tuoliken</dc:creator>
<dc:creator>Jing-Hui Li</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Restrictive cardiomyopathy with unique fibrosis pattern and familial atrial arrythmia associated with DES mutation</dc:title>
<dc:identifier>pmid:40131846</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf148</dc:identifier>
</item>
<item>
<title>Blood pressure in childhood, young- and mid-adulthood: association with carotid plaque severity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Blood pressure at each life stage contributes equally to carotid plaque presence, with mid-adulthood BP associated with a greater contribution to plaque area. These findings underscore the importance of maintaining normal BP throughout life to reduce atherosclerosis risk and suggest that intensive BP management in mid-adulthood may help slow plaque progression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf139. doi: 10.1093/eurheartj/ehaf139. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Blood pressure (BP) is a key modifiable risk factor for atherosclerosis. How BP across different life stages associates with carotid plaque in mid-adulthood remains unclear, which is the aim of this study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The sample included 1889 participants from the Cardiovascular Risk in Young Finns Study who had their BP measured in childhood (6-18 years), young adulthood (21-39 years), and mid-adulthood (40-56 years). Outcomes were the carotid plaque presence and area in mid-adulthood. A Bayesian relevant life-course exposure model was used to estimate the life-course association of BP with carotid plaque and determine the relative contributions attributed to each life stage.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After a 38-year follow-up, 745 participants (39.4%) developed carotid plaques. Cumulative systolic BP (SBP) from childhood, young-, and mid-adulthood was associated with carotid plaque presence in mid-adulthood [for each 1-SD increase (∼12 mm Hg), relative risk (95% credible intervals (CrIs)): 1.22 (1.10-1.36)], with SBP at each life stage contributing approximately equally (relative weights: childhood, 39.4%; young adulthood, 37.9%; mid-adulthood, 22.7%). Cumulative SBP was associated with carotid plaque areas [β (95% CrIs), 0.16 (0.08-0.23)] square millimetre, with mid-adulthood SBP showing a higher contribution (relative weights: childhood, 12.5%; young adulthood, 25.0%; mid-adulthood, 62.5%). Similar patterns were observed for diastolic BP, pulse pressure, and mean arterial pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Blood pressure at each life stage contributes equally to carotid plaque presence, with mid-adulthood BP associated with a greater contribution to plaque area. These findings underscore the importance of maintaining normal BP throughout life to reduce atherosclerosis risk and suggest that intensive BP management in mid-adulthood may help slow plaque progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131845</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf139>10.1093/eurheartj/ehaf139</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131845</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yaxing Meng</dc:creator>
<dc:creator>Juhani S Koskinen</dc:creator>
<dc:creator>Russell Thomson</dc:creator>
<dc:creator>Markus Juonala</dc:creator>
<dc:creator>Katja Pahkala</dc:creator>
<dc:creator>Juha Mykkänen</dc:creator>
<dc:creator>Suvi P Rovio</dc:creator>
<dc:creator>Mika Kähönen</dc:creator>
<dc:creator>Terho Lehtimäki</dc:creator>
<dc:creator>Jorma S A Viikari</dc:creator>
<dc:creator>Olli T Raitakari</dc:creator>
<dc:creator>Costan G Magnussen</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Blood pressure in childhood, young- and mid-adulthood: association with carotid plaque severity</dc:title>
<dc:identifier>pmid:40131845</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf139</dc:identifier>
</item>
<item>
<title>Emphasizing life-course prevention for atherosclerosis with focus on blood pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf159. doi: 10.1093/eurheartj/ehaf159. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf159>10.1093/eurheartj/ehaf159</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131844</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Arno Schmidt-Trucksäss</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Emphasizing life-course prevention for atherosclerosis with focus on blood pressure</dc:title>
<dc:identifier>pmid:40131844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf159</dc:identifier>
</item>
<item>
<title>Criss-cross heart with double-outlet right ventricle and interrupted aortic arch in a rare adult survivor: computed tomography insights</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf158. doi: 10.1093/eurheartj/ehaf158. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf158>10.1093/eurheartj/ehaf158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131843</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Wei-Feng Yan</dc:creator>
<dc:creator>Jin Wang</dc:creator>
<dc:creator>Zhi-Gang Yang</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Criss-cross heart with double-outlet right ventricle and interrupted aortic arch in a rare adult survivor: computed tomography insights</dc:title>
<dc:identifier>pmid:40131843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf158</dc:identifier>
</item>
<item>
<title>Acute myocardial infarction diagnosis: impact of artificial intelligence-powered ECG interpretation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf142. doi: 10.1093/eurheartj/ehaf142. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131842</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf142>10.1093/eurheartj/ehaf142</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131842</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>I Min Chiu</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute myocardial infarction diagnosis: impact of artificial intelligence-powered ECG interpretation</dc:title>
<dc:identifier>pmid:40131842</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf142</dc:identifier>
</item>
<item>
<title>Cardiac angiomyolipoma in the right atrioventricular groove: imaging characteristics and surgical approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf150. doi: 10.1093/eurheartj/ehaf150. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131840</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf150>10.1093/eurheartj/ehaf150</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131840</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Guohui Lin</dc:creator>
<dc:creator>Kai Yang</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac angiomyolipoma in the right atrioventricular groove: imaging characteristics and surgical approach</dc:title>
<dc:identifier>pmid:40131840</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf150</dc:identifier>
</item>
<item>
<title>Understanding the Cardiovascular Impacts of Heatwaves: Moving Beyond Simple Definitions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 17:S0735-1097(25)00365-1. doi: 10.1016/j.jacc.2025.02.012. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131260</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.012>10.1016/j.jacc.2025.02.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131260</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lingzhi Chu</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding the Cardiovascular Impacts of Heatwaves: Moving Beyond Simple Definitions</dc:title>
<dc:identifier>pmid:40131260</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.012</dc:identifier>
</item>
<item>
<title>Nonlinear Relation Between Cardiac Mortality and Excess Temperature in Heatwaves: Exposure Response in 2.39 Million Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The heatwave-HD relationships show nonlinear trends with risk thresholds for daytime-only and nighttime-only heatwaves, but a near-linear pattern for compound heatwaves. Amid global warming, the use of a traditional binary definition could underestimate the mortality risk and burden of HD patients associated with heatwaves. These findings highlight the need for disease-specific health care measures tailored to different heatwave types to better manage cardiac risks in a warming...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 13:S0735-1097(25)00339-0. doi: 10.1016/j.jacc.2025.01.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Short-term exposure to heatwaves has been associated with elevated heart disease (HD) mortality; however, the exposure-response relationship curves remain unexplored due to conventional binary heatwave definitions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to explore exposure-response curves for the associations between heatwaves and mortality from various cardiac causes using excess cumulative temperatures in heatwaves (ECT-HW).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide, individual-level, case-crossover study collected HD death records of all individuals across Mainland China from 2013 to 2019. We first defined daytime-only, nighttime-only, and day-night compound heatwaves using a bivariate approach, and then calculated the ECT-HW metric. We applied conditional logistic regressions with distributed lag nonlinear models to explore exposure-response curves, which were then used to estimate the corresponding mortality burden. Effects estimated using the traditional binary heatwave definition were compared with those derived from our ECT-HW metric.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We evaluated 2,392,254 HD deaths. Mortality risks associated with compound heatwaves exhibited a steady increase across the entire range of ECT-HW, without discernible thresholds. By contrast, risks from nighttime-only heatwaves emerged beyond the 25th percentile of ECT-HW and stabilized after the 90th percentile, whereas risks from daytime-only heatwaves plateaued between the 50th and 95th percentiles before rising again. Compound heatwaves demonstrated a significantly higher HD mortality risk (OR: 1.86) than nighttime-only (OR: 1.16) and daytime-only (OR: 1.19) heatwaves. A total of 41,869, 9,092, and 9,809 excess cardiac deaths were estimated to be associated with compound, nighttime-only, and daytime-only heatwaves, accounting for 1.75%, 0.38%, and 0.41% of total HD deaths, respectively. These estimates exceeded those derived from the traditional heatwave metric, which were 27,036, 2,871, and 4,785, respectively. Sudden cardiac arrest, acute myocardial infarction, and heart failure showed the highest sensitivity to compound heatwaves, whereas pulmonary heart disease exhibited the lowest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The heatwave-HD relationships show nonlinear trends with risk thresholds for daytime-only and nighttime-only heatwaves, but a near-linear pattern for compound heatwaves. Amid global warming, the use of a traditional binary definition could underestimate the mortality risk and burden of HD patients associated with heatwaves. These findings highlight the need for disease-specific health care measures tailored to different heatwave types to better manage cardiac risks in a warming climate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131259</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.034>10.1016/j.jacc.2025.01.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131259</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Xue Yu</dc:creator>
<dc:creator>Jiangdong Liu</dc:creator>
<dc:creator>Peng Yin</dc:creator>
<dc:creator>Ya Gao</dc:creator>
<dc:creator>Cheng He</dc:creator>
<dc:creator>Haidong Kan</dc:creator>
<dc:creator>Maigeng Zhou</dc:creator>
<dc:creator>Yong Huo</dc:creator>
<dc:creator>Renjie Chen</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Nonlinear Relation Between Cardiac Mortality and Excess Temperature in Heatwaves: Exposure Response in 2.39 Million Patients</dc:title>
<dc:identifier>pmid:40131259</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.034</dc:identifier>
</item>
<item>
<title>The Fontan Adult Brompton clinical score and mortality risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This novel, readily available, externally validated, clinical score identifies adult patients with a Fontan palliation at risk of mortality or transplantation and can be applied towards personalized care in this growing population with complex congenital heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf137. doi: 10.1093/eurheartj/ehaf137. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Adults with congenital heart disease who underwent a Fontan palliation are at increased risk of premature death. This study aimed to identify a risk score based on widely available clinical variables at the first adult visit and facilitate personalized care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A single tertiary centre retrospective study included adults with a Fontan circulation during their first adults with congenital heart disease outpatient visit. Anatomic and periprocedural data, clinical, laboratory, and echocardiographic parameters at the first visit, and mortality or heart transplantation data were examined. A stepwise backward conditional approach was used to build a multivariate prognostic model, validated in an external retrospective cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 230 patients (49.6% female), the median age of 21.7 [interquartile range (IQR) 18.7-28.0] years, were included. Within 10.2 years of follow-up, 44 patients died and two received heart transplantation. A score including age at the first visit, history of atrial tachyarrhythmia, heart failure, New York Heart Association class, systolic blood pressure, and resting arterial oxygen saturation was derived, discriminating patients into low, intermediate, and high risk of death or transplantation [C-index: 0.71, 95% confidence interval (CI) 0.62-0.80]; discriminative ability was excellent (C-index 0.92, 95% CI 0.90-0.95) when externally validated in a cohort of 80 patients [41.2% female, median age 18.4 (IQR 17.3-24.8) years] with similar freedom from transplantation survival with the derivation cohort (log-rank P = .77).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This novel, readily available, externally validated, clinical score identifies adult patients with a Fontan palliation at risk of mortality or transplantation and can be applied towards personalized care in this growing population with complex congenital heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131022</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf137>10.1093/eurheartj/ehaf137</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131022</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Claudia Montanaro</dc:creator>
<dc:creator>Alexandra Arvanitaki</dc:creator>
<dc:creator>William Kerrigan</dc:creator>
<dc:creator>Zehra Kadani</dc:creator>
<dc:creator>Rosaria Barracano</dc:creator>
<dc:creator>Giancarlo Scognamiglio</dc:creator>
<dc:creator>Aleksander Kempny</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:creator>Ella McDonnell</dc:creator>
<dc:creator>Hajar Habibi</dc:creator>
<dc:creator>Konstantinos Dimopoulos</dc:creator>
<dc:creator>Isma Rafiq</dc:creator>
<dc:creator>Heng Ee Ling</dc:creator>
<dc:creator>Harith Alam</dc:creator>
<dc:creator>Berardo Sarubbi</dc:creator>
<dc:creator>Gerhard-Paul Diller</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Fontan Adult Brompton clinical score and mortality risk</dc:title>
<dc:identifier>pmid:40131022</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf137</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Uncoupling thrombosis from hemostasis in atrial fibrillation? An AZALEA surfing over troubled water</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf145. doi: 10.1093/eurheartj/ehaf145. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131021</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf145>10.1093/eurheartj/ehaf145</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131021</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mattia Galli</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Uncoupling thrombosis from hemostasis in atrial fibrillation? An AZALEA surfing over troubled water</dc:title>
<dc:identifier>pmid:40131021</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf145</dc:identifier>
</item>
<item>
<title>Routine left atrial appendage surgical closure for all patients undergoing cardiac surgery?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf122. doi: 10.1093/eurheartj/ehaf122. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131020</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf122>10.1093/eurheartj/ehaf122</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131020</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Andrea Colli</dc:creator>
<dc:creator>Laura Besola</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Routine left atrial appendage surgical closure for all patients undergoing cardiac surgery?</dc:title>
<dc:identifier>pmid:40131020</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf122</dc:identifier>
</item>
<item>
<title>Less harmful alternative for smoking: addressing concerns on the observational study of electronic cigarettes and cardiovascular outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40131016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327121424&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 25:ehaf153. doi: 10.1093/eurheartj/ehaf153. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40131016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327121424&v=2.18.0.post9+e462414">40131016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf153>10.1093/eurheartj/ehaf153</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40131016</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Less harmful alternative for smoking: addressing concerns on the observational study of electronic cigarettes and cardiovascular outcomes</dc:title>
<dc:identifier>pmid:40131016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf153</dc:identifier>
</item>





























</channel>
</rss>